Michael N Weedon

Has grant

Associate Professor

University of Exeter Medical School
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

The genetics of sleep patterns and their relationship to obesity and Type 2 diabetes

Open Date: 2017-03-31

Close Date: 2019-03-31

Grant: Close

Developing a Type 1 diabetes genetic risk score to get the right diagnosis and the right treatment for patients with diabetes

Open Date: 2016-01-01

Close Date: 2018-12-31

Grant: Close

MICA: MRC APBI STratification and Extreme Response Mechanism IN Diabetes - MASTERMIND

Open Date: 2015-07-31

Close Date: 2021-05-30

Grant: Close

Identifying non-coding mutations in early-onset diabetes

Open Date: 2014-11-30

Close Date: 2017-11-29

Grant: Close

MRC APBI STratification and Extreme Response Mechanism IN Diabetes - MASTERMIND

Open Date: 2013-02-25

Close Date: 2016-06-29

Articles (7)

Sleep disorders affect over 30% of the U.S population and are linked to increased disease risk and mortality. However, the genetic architecture of sleep disorders and the overlap of sleep disorders with habitual sleep quality, quantity, and timing have been poorly characterized. In addition, it is unknown if clinical sleep disorders are extremes of habitual sleep traits. Here, we systematically investigated the genetic basis of seven clinical sleep disorder traits, and sixteen medications used for sleep problems in 1,600,000 individuals. We identified 590 genetic associations for sleep apnea, insomnia, restless legs syndrome, narcolepsy and a combined sleep disorder phenotype, of which 367 were previously unreported. Additionally, we discovered 142 genetic associations with sleep medication use. While overall genetic architecture was shared across sleep traits, we found unique genetic factors for the different sleep disorders that reflect fundamentally different biological mechanisms including for example autoimmune processes with narcolepsy and skeletal morphology in sleep apnea. Furthermore, sleep genetic factors showed a broad multi-omic impact on gene and protein expression levels. These findings suggest that while clinical sleep disorders share genetic architecture with each other and with variation in sleep patterns within the general population, they are not simply extremes of normal sleep variation but involve unique biological mechanisms. These results advance our understanding of sleep disorders and suggest potential novel therapeutic targets.

Year:

2025

As GWAS studies move from array-based genotyping to whole exome and genome sequencing, there is a significant increase in cost. Applying an appropriate technique for the selection of which controls to include, in large studies where more potential controls are available than needed for the study, may be a useful technique for minimising resource intensity while maintaining statistical power. We evaluated three control selection strategies in prostate cancer GWAS using 15,250 UK Biobank cases: (a) all controls, (b) matched controls, and (c) random selection. Both (b) and (c) achieved comparable power in detecting significant loci relative to (a), but matched controls (b) showed greater consistency in identifying leading SNPs. However, using (b) matched controls reduced discovery power by ~30% compared with (a) all controls, highlighting a trade-off. Matching controls (1:4 ratio) offers a cost-effective approach for targeted SNP analysis across phenotypes but may miss novel associations.

Year:

2025

Aims/Hypothesis GCK-MODY (Glucokinase-Maturity Onset Diabetes of the Young) causes lifelong, mild hyperglycaemia with high penetrance. Variation in glycaemic phenotype among carriers remains unexplained. We hypothesised that polygenic background contributes to this variability. Methods To test whether polygenic background contributes to the GCK-MODY clinical phenotype, we analysed polygenic risk scores (PGS) for nine diabetes-related traits in 901 clinically referred individuals with GCK-MODY. We compared these to 7,645 non-diabetic controls and assessed associations between PGS’s and glycaemic measures. Additionally, we evaluated 158 unselected GCK variant carriers from the UK Biobank to examine polygenic effects independent of clinical referral. Results We observed independent polygenic enrichment for HbA1c (including both glycaemic and non- glycaemic components), fasting glucose, and type 2 diabetes in clinically referred GCK-MODY individuals (0.16-0.33 SD higher, all P < 0.003), but not for type 1 diabetes. In contrast, no such enrichment was seen in GCK pathogenic variant carriers from a clinically unselected population- based cohort. In both settings, HbA1c PGSs were associated with measured HbA1c levels in GCK carriers (β = 0.91- 0.97, all P < 0.009), with effect sizes similar to those in non-carriers. GCK-MODY cases in the top HbA1c quintile had a 3-to-6-fold risk of exceeding the diabetes diagnostic HbA1c threshold (≥ 48 mmol/mol) in clinically selected and clinically unselected cohort respectively. Conclusions/interpretation Our findings suggest that polygenic background and GCK variants interact to modify the glycaemic expression of GCK-MODY, influencing clinical diagnosis despite high penetrance. Our study highlights the importance of integrating both monogenic and polygenic factors to better understand phenotypic variability in monogenic diseases. Research in Context What is already known about the subject? Although GCK-MODY shows high penetrance, individuals vary in their glycaemic phenotype, and the cause of this variability remains unclear. Polygenic background has previously been found to modify disease risk and phenotypic variability in other lower penetrant forms of MODY but its contribution to the clinical variability in GCK-MODY is largely unexplored What is the key question? Does polygenic background for diabetes-related traits contribute to variation in the GCK- MODY phenotype? What are the new findings? We identified that clinically referred GCK-MODY cases had an independent enrichment of HbA1c, fasting glucose, and type 2 diabetes polygenic background, potentially increasing the likelihood of clinical referral. Higher HbA1c polygenic risk in GCK-MODY was associated with elevated measured HbA1c levels and an increased probability of exceeding the diagnostic threshold for diabetes. How might this impact on clinical practice in the foreseeable future? Polygenic background shapes the clinical expression of GCK-MODY, supporting the integration of monogenic and polygenic information to explain variability in monogenic disease.

Year:

2025

Context Diagnosing Maturity-Onset Diabetes of the Young (MODY) is clinically important for treatment and prognosis. However, phenotype-based studies of MODY are prone to ascertainment bias, limiting accurate estimates of its population prevalence and phenotypic spectrum. Objective To apply a genotype-first approach to determine the population prevalence, penetrance, and all-cause mortality associated with MODY. Methods We analysed exome sequencing and clinical data from 454,275 UK Biobank participants to identify pathogenic variants in 10 established MODY genes. We assessed variant prevalence, age-dependent diabetes penetrance, and all-cause mortality by genetic aetiology over a mean follow-up of 13.4 years. Results Pathogenic MODY variants were present in 1 in 1,052 individuals and accounted for 1.48% of diabetes cases diagnosed before age 40. GCK variants were the most frequent (1 in 2,787), demonstrating high penetrance (mean HbA1c 8.8 mmol/mol higher; 94.5% with prediabetes or diabetes) but no significant association with all-cause mortality ( P =0.09). Variants in other MODY genes showed lower penetrance, with 12% of carriers developing diabetes by age 40 and 31.6% by age 60 and showed no increase in all-cause mortality ( P =0.89). Penetrance varied by genetic aetiology, with HNF1A showing the highest penetrance and PDX1 , NEUROD1 , and RFX6 the lowest. Parental history of diabetes and polygenic risk for type 2 diabetes were important modifiers of penetrance (Hazard ratios 2.54 and 1.52 respectively, P <3.9×10 −3 ). Conclusions This large-scale genotype-first study provides novel insights into MODY in the population. These findings have broad implications for genetic counselling, personalised treatment strategies, and healthcare resource allocation.

Year:

2025

The contribution of polygenic background in young onset monogenic disorders needs further exploration. Understanding this will provide new biological insights and may improve risk prediction of monogenic disease. Here we investigated the role of polygenic background in MODY—a common monogenic disorder with an age-dependent onset.We found strong enrichment of type 2 diabetes (T2D) polygenic risk, but not type 1 diabetes risk, in genetically confirmed MODY cases. This T2D polygenic burden, primarily through beta-cell dysfunction pathways, was strongly associated with earlier age of diagnosis and increased diabetes severity. Common genetic variants collectively accounted for 24% (p<0.0001) of the phenotypic variability. Using a large population cohort, we demonstrated that T2D polygenic burden substantially modifies diabetes onset in individuals with pathogenic variants, with diabetes risk ranging from 11% to 81%. Finally, we show that individuals with MODY-like phenotypes without a causal variant had elevated polygenic burden for T2D and related traits representing potential polygenic phenocopies. These findings reveal substantial influence of common genetic variation in shaping the clinical presentation of early-onset monogenic disorders. Incorporating these may improve risk estimates for individuals carrying pathogenic monogenic variants.

Year:

2025

Objectives Genetic Risk scores (GRS) classify diabetes types, type 1 (T1D) and type 2 (T2D) in Europeans but the power is limited in other ancestries. We explored the performance of T1DGRS and potential reasons for inferior discrimination ability in diabetes-type classification in Indians. Research Design and Methods In a well-characterized Indian cohort comprising 645 clinically diagnosed T1D, 1153 T2D and 327 controls, we estimated the discriminative ability of T1DGRS (comprising 67 SNPs from Europeans) using receiver operating characteristics-area under the curve (ROC-AUC). We also compared the islet autoantibody status (AA), frequency and effect size of various HLA alleles/haplotypes between Indians and Europeans. Results The T1DGRS was discriminative of T1D from T2D and controls but the ability is lower in Indians than Europeans (AUC=0.83 vs 0.92 respectively, p<0.0001). The T1DGRS was higher in AA-positive patients compared to AA-negative patients [13.01 (12.79-13.23) vs 12.09 (11.64-12.56)], p<0.0001) and showed greater discrimination in the AA-positive T1D (ROC-AUC 0.85). While association of common HLA-DQA1∼HLA-DQB1 haplotypes with T1D is replicated, important differences in the risk allele frequency, nature/direction and magnitude of association between Indians and Europeans were noted. Conclusions A T1DGRS derived from Europeans is discriminative of T1D in Indians, highlighting similarity in heritability of T1D. Differences in allele frequency, effect size and directionality, especially in the HLA region are important contributors to inferior discrimination performance of T1DGRS in Indians. Further studies of diverse populations may improve its performance.

Year:

2024

Context PLIN1 encodes perilipin-1, which coats lipid droplets in adipocytes and is involved in droplet formation, triglyceride storage, and lipolysis. Rare PLIN1 frameshift variants that extend the translated protein have been described to cause lipodystrophy. Objective This work aimed to test whether PLIN1 protein-truncating variants (PTVs) cause lipodystrophy in a large population-based cohort. Methods We identified individuals with PLIN1 PTVs in individuals with exome data in the UK Biobank. We performed gene-burden testing for individuals with PLIN1 PTVs. We replicated the associations using data from the T2D Knowledge portal. We performed a phenome-wide association study using publicly available association statistics. A total of 362 791 individuals in the UK Biobank, a population-based cohort, and 43 125 individuals in the T2D Knowledge portal, a type 2 diabetes (T2D) case-control study, were included in the analyses. Main outcome measures included 22 diseases and traits relevant to lipodystrophy. Results The 735 individuals with PLIN1 PTVs had a favorable metabolic profile. These individuals had increased high-density lipoprotein cholesterol (0.12 mmol/L; 95% CI, 0.09 to 0.14, P = 2 × 10–18), reduced triglycerides (–0.22 mmol/L; 95% CI, –0.29 to –0.14, P = 3 × 10–11), reduced waist-to-hip ratio (–0.02; 95% CI, –0.02 to –0.01, P = 9 × 10–12), and reduced systolic blood pressure (–1.67 mm Hg; 95% CI, –3.25 to –0.09, P = .05). These associations were consistent in the smaller T2D Knowledge portal cohort. In the UK Biobank, PLIN1 PTVs were associated with reduced risk of myocardial infarction (odds ratio [OR] = 0.59; 95% CI, 0.35 to 0.93, P = .02) and hypertension (OR = 0.85; 95% CI, 0.73 to 0.98, P = .03), but not T2D (OR = 0.99; 95% CI, 0.63-1.51, P = .99). Conclusion Our study suggests that PLIN1 haploinsufficiency causes a favorable metabolic profile and may protect against cardiovascular disease.

Year:

2022

Collaborators (11)

Hanna Ollila

University of Helsinki

FINLAND
View details

Kashyap A Patel

University of Exeter Medical School

UNITED KINGDOM
View details

Richard Oram

Diabetes UK Harry Keen Fellow, Senior Clinical Lecturer and Honorary Consultant

University of Exeter

UNITED KINGDOM
View details

Tian Ge

Broad Institute

UNITED STATES
View details

Robin N Beaumont

University of Exeter

UNITED KINGDOM
View details

Johan H Thygesen

Associate Professor

University College London

UNITED KINGDOM
View details

Thomas Laver

Senior Lecturer in Human Genetics

University of Exeter

UNITED KINGDOM
View details

Andrew Wood

Lecturer in Statistical Genetics and Health Data Science

University of Exeter

UNITED KINGDOM
View details

Jacqueline Lane

Assistant Professor

Brigham and Women's Hospital

UNITED STATES
View details

Richa Saxena

Professor of Anaesthesia

Harvard Medical School

UNITED STATES
View details

Andrew Hattersley

Professor of Molecular Medicine

University of Exeter

UNITED KINGDOM
View details